Literature DB >> 22960850

Monoamine oxidase inhibitors and neuroprotection: a review.

Saleem K Al-Nuaimi1, Erin M Mackenzie, Glen B Baker.   

Abstract

Monoamine oxidase inhibitors have been available for more than 50 years, initially developed as antidepressants but currently used in a variety of psychiatric and neurological conditions. There has been a recent surge of interest in monoamine oxidase inhibitors because of their reported neuroprotective and/or neurorescue properties. Interestingly, it seems that often these properties are independent of their ability to inhibit monoamine oxidase. This review article presents an overview of the neuroprotective/neurorescue properties of these multifaceted drugs and focuses on phenelzine, (-)-deprenyl, rasagiline, ladostigil, tranylcypromine, moclobemide, and clorgyline and their possible neuroprotective mechanisms.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22960850     DOI: 10.1097/MJT.0b013e31825b9eb5

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  11 in total

Review 1.  Pharmacological neuroprotection and clinical trials of novel therapies for neonatal peri-intraventricular hemorrhage: a comprehensive review.

Authors:  Taylor Reardon; Gretchen Koller; Michael W Kortz; Edwin McCray; Blake Wittenberg; Todd C Hankinson
Journal:  Acta Neurol Belg       Date:  2022-02-19       Impact factor: 2.396

2.  The amine oxidase inhibitor phenelzine limits lipogenesis in adipocytes without inhibiting insulin action on glucose uptake.

Authors:  Christian Carpéné; Sandra Grès; Simon Rascalou
Journal:  J Neural Transm (Vienna)       Date:  2012-12-16       Impact factor: 3.575

3.  Effects of anti-depressant treatments on FADD and p-FADD protein in rat brain cortex: enhanced anti-apoptotic p-FADD/FADD ratio after chronic desipramine and fluoxetine administration.

Authors:  M Julia García-Fuster; Jesús A García-Sevilla
Journal:  Psychopharmacology (Berl)       Date:  2016-06-03       Impact factor: 4.530

4.  Combination of low dose of the anti-adipogenic agents resveratrol and phenelzine in drinking water is not sufficient to prevent obesity in very-high-fat diet-fed mice.

Authors:  C Carpéné; S Gomez-Zorita; R Gupta; S Grès; C Rancoule; T Cadoudal; J Mercader; A Gomez; C Bertrand; Z Iffiu-Soltész
Journal:  Eur J Nutr       Date:  2014-02-15       Impact factor: 5.614

5.  The Concise Guide to PHARMACOLOGY 2013/14: enzymes.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

6.  Eryptosis as a marker of Parkinson's disease.

Authors:  Etheresia Pretorius; Albe C Swanepoel; Antoinette V Buys; Natasha Vermeulen; Wiebren Duim; Douglas B Kell
Journal:  Aging (Albany NY)       Date:  2014-10       Impact factor: 5.682

Review 7.  Monoaminergic Mechanisms in Epilepsy May Offer Innovative Therapeutic Opportunity for Monoaminergic Multi-Target Drugs.

Authors:  Dubravka Svob Strac; Nela Pivac; Ilse J Smolders; Wieslawa A Fogel; Philippe De Deurwaerdere; Giuseppe Di Giovanni
Journal:  Front Neurosci       Date:  2016-11-10       Impact factor: 4.677

Review 8.  Plants-Derived Neuroprotective Agents: Cutting the Cycle of Cell Death through Multiple Mechanisms.

Authors:  Taiwo Olayemi Elufioye; Tomayo Ireti Berida; Solomon Habtemariam
Journal:  Evid Based Complement Alternat Med       Date:  2017-08-22       Impact factor: 2.629

9.  Dietary Phenolic Compounds Interfere with the Fate of Hydrogen Peroxide in Human Adipose Tissue but Do Not Directly Inhibit Primary Amine Oxidase Activity.

Authors:  Christian Carpéné; Mounia Hasnaoui; Balázs Balogh; Peter Matyus; Alfredo Fernández-Quintela; Víctor Rodríguez; Josep Mercader; Maria P Portillo
Journal:  Oxid Med Cell Longev       Date:  2016-01-05       Impact factor: 6.543

10.  Marine natural products with monoamine oxidase (MAO) inhibitory activity.

Authors:  Ahreum Hong; Le Cam Tu; Inho Yang; Kyung-Min Lim; Sang-Jip Nam
Journal:  Pharm Biol       Date:  2020-12       Impact factor: 3.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.